
Gels, Journal Year: 2024, Volume and Issue: 10(9), P. 583 - 583
Published: Sept. 11, 2024
There is a lack of information about transforming growth factor beta-1 (TGF-β
Language: Английский
Gels, Journal Year: 2024, Volume and Issue: 10(9), P. 583 - 583
Published: Sept. 11, 2024
There is a lack of information about transforming growth factor beta-1 (TGF-β
Language: Английский
Mechanisms of Ageing and Development, Journal Year: 2025, Volume and Issue: unknown, P. 112039 - 112039
Published: Feb. 1, 2025
Language: Английский
Citations
0Renal Failure, Journal Year: 2025, Volume and Issue: 47(1)
Published: April 3, 2025
Transforming growth factor-beta (TGF-β), a cytokine with near omnipresence, is an integral part of many vital cellular processes across the human body. The family includes three isoforms: 1, 2, and 3. These cytokines play significant role in fibrosis cascade. Diabetic kidney disease (DKD), major complication diabetes, increasing prevalence daily, classical diagnosis diabetes based on presence albuminuria. occurrence nonalbuminuric DKD has provided new insight into pathogenesis this disease. emphasis multifactorial pathways involved developing highlighted some markers associated tissue fibrosis. In diabetic nephropathy, TGF-β significantly its pathology. Its serum urine means that it could be diagnostic tool while regulation provides potential therapeutic targets. Completely blocking signaling reach untargeted regions cause unanticipated effects. This paper reviews basic details as cytokine, DKD, updates research carried out to validate candidacy.
Language: Английский
Citations
0Biomolecules, Journal Year: 2025, Volume and Issue: 15(4), P. 595 - 595
Published: April 16, 2025
Osteonecrosis of the jaw (ONJ), including maxilla and mandible, is considered a challenging therapeutic problem, mainly due to lack understanding its pathogenesis. It well known that ONJ severe side effect caused by certain medications used treat bone metastasis osteoporosis, such as bisphosphonates, which inhibit resorption. Other therapeutics with similar effects are, for instance, receptor activators nuclear factor kappa-B ligand (RANK-L) inhibitor (denosumab), tyrosine kinase inhibitors (sunitinib), antiangiogenics (bevacizumab). The conservative or surgical treatment these medication-related osteonecroses (MRONJs) generally effortful still not entirely effective. Therefore, research seeks alternative options like tissue engineering stem cell therapy, predominantly represent mesenchymal cells (MSCs) their derivatives, extracellular vesicles. Moreover, it was published novel therapy could even prevent onset MRONJ. On other hand, administration may also be accompanied some health risks, an increased chance cancer occurrence in patients. current review paper summarizes most recent progress stem-cell-based stem-cell-free ONJ. Similarly, we discuss this approach’s future perspectives possible obstacles.
Language: Английский
Citations
0Gels, Journal Year: 2024, Volume and Issue: 10(9), P. 583 - 583
Published: Sept. 11, 2024
There is a lack of information about transforming growth factor beta-1 (TGF-β
Language: Английский
Citations
0